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Abstract Proteinase 3, which is known as an intraeellular serine 
protease of neutrophils, was detected at the surface of a suhpop- 
nlation of freshly isolated PMN. The proportion of PR3-positive 
and -negative PMN, observed by flow cytometry with anti-PR3 
mAbs or ANCA autoantibodies, varies among individuals but is 
extremely stable for each individual over prolonged time periods. 
After PMN degranulation by FMLP with cyt. B, membrane PR3 
expression increases but the proportion of low and high PR3- 
expressing cells remains stable. The existence of a subset of PMN 
which spontaneously expresses PR3 and varies among individu- 
als, may be relevant to the pathogenesis of anti-PR3 ANCA 
antoantibody-related vasculitis. 
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1. Introduction 
Proteinase 3 (PR3) is a serine protease present in azurophil 
granules of polymorphonuclear neutrophils (PMN) and origi- 
nally described as an enzyme which degrades elastin and causes 
pulmonary emphysema after intratracheal instillation in ham- 
sters [1,2]. It was subsequently identified to myeloblastin, an 
enzyme involved in the proliferation and the control of differen- 
tiation of HL-60 cell lines [3]. Most importantly, PR3 is the 
main antigenic target of antineutrophil cytoplasmic autoanti- 
bodies (ANCA) observed in Wegener's granulomatosis (WG) 
[4,5]. It belongs to the family of neutrophil serine proteases with 
bactericidal ctivity, also called 'serprocidins', which includes 
neutrophil elastase, cathepsin G, PR3 and the enzymatically 
inactive azurocidin [6,7]. 
These enzymes are supposed to function mainly intracellu- 
larly after the fusion of azurophil granules with phagocytic 
vacuoles and to be only released into the extracellular space by 
'leakage' during extensive phagocytosis [1,8,9]. 
On the other hand, the close correlation observed in WG 
between systemic vasculitis and anti-PR3 ANCAs [10-12] sug- 
gests that anti-PR3 autoantibodies ither trigger or amplify 
neutrophil activation, resulting in cell aggregation and release 
of inflammatory mediators responsible for endothelium dam- 
age. This hypothesis implies an extracellular localization of 
PR3 accessible to anti-PR3 ANCAs. 
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Abbreviations: PR3, proteinase 3;PMN, polymorphonuclear neutro- 
phils; ANCA, antineutrophil cytoplasmic autoantibodies; WG, 
Wegener's granulomatosis; HBSS, Hanks' balanced salt solution; cyt. 
B, cytochalasin B; fMLP, N-formyl-methionyl-leucyl-phenylalanine. 
While analysing the conditions of in vitro neutrophil activa- 
tion resulting in PR3 exocytosis, we observed that a proportion 
of unactivated, freshly isolated PMN expressed PR3 on their 
surface as shown by flow cytometry. Most surprisingly, this 
proportion of PR3-positive cells was found to vary between 0
and 90% among the blood donor population while being ex- 
tremely stable for one given individual. We here analyse this 
phenomenon which reveals a phenotypic heterogeneity of neu- 
trophils and could be relevant to the pathogenic role of anti- 
PR3 ANCAs. 
2. Materials and methods 
2.1. PMN isolation and & vitro activation 
PMN were isolated from EDTA-anticoagulated blood from healthy 
donors by depletion of the platelet-enriched plasma, centrifugation  
Polymorphprep (Nycomed, Oslo, Norway) and lysis of contaminating 
erythrocytes. Cells were washed in Hanks' balanced salt solution 
(HBSS) without CaZ+/Mg 2+ (Gibco, Paisley, UK) and resuspended, 
either in ice-cold PBS containing 1% bovine serum albumin and 0.1% 
sodium azide (PBS/BSA/azide) for immediate incubation with antibod- 
ies for flow cytometry analysis or in warm HBSS with Ca2+/Mg 2÷ 
(Gibco) for cell activation. For in vitro cell activation, PMN 106/ml in 
HBSS with Ca2+/Mg z÷ were incubated at 37°C in BSA-coated tubes, in 
the presence ofprotease inhibitor soyabean trypsin inhibitor and oxi- 
dant scavenger methionin, 5 min with 10/~g/ml cytochalasin B (cyt. B; 
Sigma, St Louis, MO) followed by 1 h with 1/IM FMLP (Sigma). PMN 
were then centrifuged and resuspended in PBS/BSA/azide for flow 
cytometry analysis. 
Two healthy volunteers were injected s.c. with 1 mg glucagon. Blood 
samples were taken before and 2 h after the injection and PMN isolated 
as described above. 
PMN were isolated from the blood and synovial f uid of rheumatoid 
arthritis patients as described [13] by centrifugation Ficoll Hypaque 
(Pharmacia) preceeded, for blood cells, by erythrocyte s dimentation 
on plasmagel (Roger Bellon Laboratory, Neuilly-sur-Seine, France). 
2.2. Antibodies 
Murine mAb anti-PR3 CLB 12.8 was from CLB (Amsterdam, The 
Netherlands) while WGM.2 was a gift from E. Czernok (Bad Bram- 
stedt, Germany); anti-elastase AHN-10 was from Pharmingen (San 
Diego, CA), anti-elastase NP-57 from Dako (Glostrup, Denmark); 
anti-CD63 CLB-gran/12, control mouse immunoglobulin IgG1 and 
FITC-conjugated F(ab')2 fragment of goat antihuman IgG were from 
Immunotech (Marseille, France); FITC-conjugated F(ab')2 antimouse 
IgG were from Caltag Laboratories (San Francisco, CA) while FITC- 
F(ab')2 antihuman F(ab')2 was from Jackson (West Grove, PA); Anti- 
FcyRII (IV.3) and anti-FcyRIII (3G.8) mAbs were from Medarex 
(West Lebanon, NH). Anti-GPIIblIIa mAb P1873 was a gift from C. 
Kaplan (CNTS, Paris). Normal goat IgGs were from Sigma. They were 
heat-aggregated by incubating them at a concentration f 10 mg/ml for 
30 min at 60°C. 
IgGs from a patient with WG with anti-PR3 ANCA and from a 
normal control were isolated by chromatography on Protein A-Sepha- 
rose (Pharmacia, Uppsala, Sweden). F(ab')2 fragments were obtained 
after digestion with 2% w/w pepsin (Worthington, Freehold, NJ) at pH 
3 for 4 h at 37°C and further absorption of uncleaved IgGs and Fc 
fragments on protein A-sepharose. Purity of F(ab')2 fragments was 
assessed by PAGE analysis with PHAST system (Pharmacia). When 
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mentioned, antibodies were labelled with NHS-LCbiotin (Pierce, Rock- 
ford, IL) according to the manufacturer's instructions. 
2.3. Immunofluorescence flow cytometry 
106 PMN in PBS containing 1% BSA and 0.1% sodium azide were 
first incubated for 30 min at 4°C with 1 mg/ml heat-aggregated goat 
IgGs to block Fc?' receptors. Cells were then treated with dilutions of 
monoclonal ntibodies followed by FITC-conjugated F(ab')2 fragments 
of goat antimouse IgG. Cells were fixed with 1% formaldehyde and 
analysed for fluorescence on a FACScan flow cytometer (Becton Dick- 
inson Immunocytometry Systems, Mountain View, CA) with light scat- 
ter gate set. 
For whole-blood analysis, anti-PR3 antibodies were added to 
EDTA-anticoagulated blood for 15 min at room temperature. After a 
single wash in PBS/BSA/azide, the FITC-antimouse IgG antibody was 
added for 15 min at room temperature, then red cells were lysed in 
Becton Dickinson FACS lysis solution according to the manufacturer's 
instructions and fixed with 1% formaldehyde. 
2.4. Statistical analysis 
The distribution of the proportion of PR3-positive PMN in the nor- 
mal population was analysed using the Statistica Software package 
(Tulsa, OK). 
3. Results 
3.1. Heterogeneous PR3 membrane xpression on resting PMN 
Flow cytometry analysis of membrane-bound PR3 on in 
vitro activated neutrophils revealed that a proportion of PMN 
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Fig. 1. Heterogeneous expression of PR3 on freshly isolated neutro- 
phils. PMN from individual (A) were analysed by flow cytometry with 
clone CLB-12.8 or clone WGM2 anti-PR3 mAbs or with a mixture of 
two anti-elastase mAbs. Individual (B) was tested either with the CLB 
12.8 mAb or with whole IgGs from a WG patient with anti-PR3 ANCA 
or with the F(ab')2 fragments of this WG patient IgGs. The percentage 
of PR3-positive cells is mentioned. The thin peak at the left of each 
diagram is the overlayed control histogram obtained with mouse IgG1, 
normal human IgGs or F(ab')2 according to the antibody tested. 
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Fig. 2. Expression of PR3 on PMN newly recruited from the marrow 
or having migrated to an inflammation site. PMN were analysed by 
flow cytometry with CLB 12.8 anti-PR3 mAb. The thin peak at the left 
shows the control histogram obtained with mouse IgG1. PMN from 
individual (A) were tested before and 2 h after glucagon injection. 
Individual (B) was a patient with rheumatoid arthritis for whom blood 
and synovial fluid PMN were compared. 
was labelled with anti-PR3 antibodies in the absence of in vitro 
activation. A bimodal distribution was constantly observed 
when freshly isolated PMN were labelled with two different 
anti-PR3 mAbs, CLB 12.8 and WGM.2 clones, or with IgGs 
from two WG patients with anti-PR3-ANCAs (only one is 
shown) (Fig. 1). A proportion of cells was not or were weakly 
labelled while the others clearly expressed PR3. PMN tested in 
parallel with a mixture of two anti-elastase mAbs (Fig. 1) or 
with a polyclonal anti-elastase antibody (data not shown) were 
not or were weakly and homogeneously labelled. Futhermore, 
PMN analysed similarly with mAbs directed against various 
neutrophil markers, such as integrins CDl la ,  CDI lb /CD18 
and CD29, L-selectin, complement receptor CR1, FcyRI I  and 
III, CD31, CD43 and CD44, resulted in our hands in a single 
homogeneously labelled cell population (data not shown). 
The proportion of PR3-positive PMN varied from one indi- 
vidual to another but the same percentage was obtained, for 
one given individual, with the two anti-PR3 mAbs and the IgGs 
from the two WG patients (~65% for individual A, 47% for 
individual B on Fig. 1). 
Similar results were obtained whether or not Fcy receptors 
were saturated with aggregated IgGs before anti-PR3 labelling, 
except that a better resolution of the two cell peaks was ob- 
tained after Fcy receptor blocking. The same percentage of 
PR3-positive PMN was obtained with IgGs from a WG patient 
and with the F(ab')2 fragments of these patient IgG revealed 
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Fig. 3. Expression of azurophil granule markers on the plasma mem- 
brane of activated PMN. PMN were incubated for 1 h at 37°C, as 
described in Section 2, with HBSS or with 10/2g/ml cyt. B and 1/2M 
FMLP. Unactivated and activated cells were analysed by flow cyto- 
metry with CLB 12.8 anti-PR3, AHNI0 anti-elastase, CLB-gran/12 
anti-CD63 and anti-GPIlblIIa P1873 mAbs. The peak on the left repre- 
sents the overlayed control histogram obtained with mouse IgG1. 
with FITC-F(ab')2 antihuman F(ab')2 as secondary antibody 
(Fig. 1B). 
When isolated PMN were incubated with autologous 
plasma, PR3 was no more detected at the cell surface. This 
explains the negative results obtained in whole-blood analysis 
(data not shown). 
3.2. Proportion of PR3-expressing PMN is stable for one given 
individual 
When the percentage of PR3-positive cells of 7 different 
individuals was measured on two occasions distant of 12 + 9 
weeks, the results of the two evaluations were strikingly similar 
(correlation r = 0.998). Two individuals tested 5× over a period 
of 5 months resulted in 29.64 + 2.68 and 41.26 + 2.12 PR3- 
positive cells, respectively (data not shown). 
For one given individual, the observed heterogeneity in the 
blood neutrophil pool does not seem to be related to the 
amount of neutrophils newly released from the marrow or, on 
the contrary, to the amount of senescent PMN. The same 
proportion of PR3-positive cells was observed in individual A 
before and after artificial massive recruitment of marrow neu- 
trophils by in vivo injection of glucagon (Fig. 2A). This was 
observed in two different individuals (only one is shown) for 
whom the number of blood PMN was increased 4× by the 
glucagon injection. Conversely, on Fig. 2B is shown the com- 
parison of PMN at the inflammation site, i.e. in the synovial 
fluid of a patient with rheumatoid arthritis, with blood PMN 
from the same patient. The amount of membrane PR3 was 
increased on all cells from the synovial fluid but the percentage 
of PMN with high levels of membrane-bound PR3 was similar 
to that of PR3-expressing cells in the PMN-circulating pool. 
3.3. Two PMN populations with different expression of 
membrane PR3 remain distinct after in vitro cell activation 
In vitro cell activation by FMLP with cyt. B resulted in an 
increased amount of membrane PR3 on all PMN with two 
clearly distinct populations of high and low PR3-expressing 
cells in the same proportion than PR3-negative and -positive 
PMN before activation (Fig. 3). The mean fluorescence inten- 
sity of the two cell peaks was 2 and 29 units, respectively, before 
activation, 5 and 43 after activation. Membrane-bound elastase 
was also detected after cell activation but resulted in a single 
labelled peak. Stimulation by cyt. B and FMLP resulted in a 
marked de novo expression of CD63 on the cell surface, show- 
ing that indeed azurophil granules have fused with the plasma 
membrane [14]. The negative results obtained with anti- 
GPI Ibl I Ia confirmed that the positive CD63 labelling was not 
due to activated platelets which strongly express CD63 and may 
bind neutrophils [15]. 
3.4. Distribution of PR3-positive subpopulation i  normal donors 
The proportion of freshly isolated PMN expressing mem- 
brane PR3 among 42 blood donors varied within the range of 
0-95% (mean + SD = 49.64 + 20.39). When the distribution 
was depicted as a frequency histogram (Fig. 4), the pattern 
seemed to be normal-unimodal and statistical nalysis was con- 
sistent with a normal distribution (22 = 0.7, df = 3, P = NS). 
4. Discussion 
The present data show that normal circulating neutrophils 
express PR3 on their membrane with an unusual PR3 expres- 
sion phenotype which defines two distinct populations, one 
unlabelled while the other clearly expressing PR3. A remarka- 
ble feature of this PR3 expression is the high variability of the 
proportion of PR3-expressing cells among individuals, con- 
trasting with the striking stability of this proportion, over pro- 
longed periods of time, in one given individual both on resting 
and on activated PMN. An heterogeneous expression of mem- 
brane PR3 after neutrophil activation had previously been 
mentioned by Czernok et al. [16] but variations among individ- 
uals were not studied by these authors. 
This peculiar type of distribution seems to be restricted to 
PR3 since neutrophils analysed by flow cytometry with a wide 
variety of antineutrophil marker mAbs resulted in our hands 
in a single homogeneously labelled cell population. The exis- 
tence of two discrete populations of PR3-positive cells was not 
due to an artefactual interaction of anti-PR3 antibody with the 
neutrophil membrane since the same bimodal distribution and 
the same proportion of PR3-positive cells were observed with 
two different anti-PR3 mAbs or with IgGs from two WG pa- 
tients with anti-PR3 ANCAs. In addition, the binding of anti- 
PR3 antibodies did not involve the Fc portion of antibodies 
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Fig. 4. Distribution of the proportion of PR3-positive PMN among 42 
blood donors. 
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since: (1) PMN labelling with anti-PR3 mAbs was not modified 
by Fcz receptor blocking; and (2) the same proportion of PR3- 
positive cells was measured with WG patient IgG and with their 
F(ab')2 fragments. Altogether, these results strongly suggest 
that the bimodal binding of anti-PR3 antibodies to neutrophils 
is due to a true heterogeneity in PR3 membrane xpression. 
Neutrophil isolation procedures result in limited cell activa- 
tion, which modifies the expression of various markers [17] and 
could potentially induce artefactual PR3 expression on freshly 
isolated PMN. This is, however, very unlikely for two reasons. 
(1) When cells were fully activated in vitro by cyt. B and FMLP, 
which induces the release ofazurophil granule content, the level 
of membrane PR3 was found to increase proportionally on all 
PMN and two populations of low and high PR3-expressing 
cells remained clearly distinct, in the same proportion as in 
resting cells. If freshly isolated cells which express PR3 were 
simply a proportion of cells activated uring the purification 
procedures, one would expect that extensive degranulation 
would result in an homogeneous population with maximal PR3 
expression. (2) PMN from different individuals isolated on the 
same day and in the same way resulted in different proportions 
of PR3-positive cells while this proportion appeared as an ex- 
tremely stable characteristic of one given individual tested over 
a period of up to 4 months. This stability strongly argues 
against the hypothesis that variations in the cell isolation proce- 
dures would explain the differences observed among individu- 
als. We do not exclude, however, that purification steps allow 
to reveal the constitutive PMN heterogeneity described here, 
since we were not able to detect membrane PR3 on PMN in 
whole blood, presumably because of interferences of plasma 
factor(s) with anti-PR3 antibody binding. 
Antigenic and functional heterogeneities of mature neutro- 
phils have been previously described [18]. Various techniques 
of cell fractionation by density centrifugation or flow electro- 
phoresis revealed physicochemical and functional heterogene- 
ity in the circulating neutrophil pool [19-21]. Some of these 
variations concerned azurophil or specific granule components 
defining subpopulations of PMN with differences in myeloper- 
oxidase or lactoferrin activity [22,23]. None of these studies, 
however, pointed out to individual and possibly genetic differ- 
ences in the proportion of PMN subsets. Specific monoclonal 
antibodies (31D8, PMN 6, AML.2.23) also allowed to distin- 
guish PMN subpopulations with maturational and/or func- 
tional differences [24~26]. The percentage of cells bearing these 
antigens, which to our knowledge have not been characterized 
so far, vary among individuals but the stability of this distribu- 
tion for a given individual was not mentioned by these authors. 
By analogy with reported heterogeneities in the PMN pool 
related to cell maturation differences or to the presence of 
apoptotic ells [26,27], the expression of PR3 might be related 
to the 'age' of neutrophils. This seems unlikely since the propor- 
tion of PR3-expressing cells was the same in PMN newly re- 
cruited from the bone marrrow by in vivo glucagon treatment 
as in the normal circulating cells of the same subject before 
treatment. Furthermore, the subpopulation f PMN expressing 
high levels of PR3 among cells recovered from the synovial 
fluid of a rheumatoid arthritis patient represented the same 
percentage of the total PMN pool having reached the inflam- 
matory site than the PR3-positive subset in the blood from the 
same patient. 
Both the origin of membrane PR3 and the interaction be- 
tween PR3 and the neutrophil membrane remain to be eluci- 
dated. Membrane PR3 is unlikely to result from azurophil 
granule mobilization since CD63, which is a sensitive marker 
of azurophil granule exocytosis [15], was absent or weakly ex- 
pressed on freshly isolated PMN independently of the impor- 
tance of the PR3-positive population. This contrasted with the 
massive membrane xpression of CD63 induced by degranu- 
lating stimuli, such as cyt. B and FMLP, which resulted in a 
modest increase of membrane PR3 level. Can PR3 be inserted 
in the membrane or is it secreted then bound to a receptor? A
membrane receptor for elastase, another azurophil granule en- 
zyme closely related to PR3, has indeed be reported on PMN 
[28]. Furthermore, the highly basic PR3 molecule could bind 
to negatively charged components of the cell glycocalyx and 
charge heterogeneities have been described in the neutrophil 
pool [21]. 
The molecular basis of the heterogeneity among mature neu- 
trophils is not known from this study but the stability, for one 
given subject, of the proportion of this PMN subset suggests 
that it may be under genetic ontrol. Family studies are now 
required to ascertain this point. If such a genetic ontrol exists, 
it could be relevant o the occurrence of WG vasculitis which 
in most cases is associated with anti-PR3 ANCA autoantibod- 
ies. The existence of a PMN subpopulation naturally expressing 
PR3 and its variability among individuals may be involved in 
the pathogenesis of ANCA-related iseases. Indeed, the expo- 
sure of PR3 on the cell surface could favour the autoimmuniza- 
tion and/or allow the binding of anti-PR3 autoantibodies to
neutrophils which may amplify the PMN-induced vascular in- 
flammation. The analysis of PR3 expression on PMN from WG 
patients will be required to see if a high proportion of PR3- 
expressing ceils predisposes to the disease. 
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